A decades-old drug used to lower cholesterol levels in the blood has been shown to reduce the progression of vision-robbing retinopathy in people with diabetes.
Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without
Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabete
In a conversation held earlier in the year as the four-year anniversary of the pandemic approached, the pharmaphorum podcast had as guest Murray Aitken, executive director of the
Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM) to be approved by the FDA, Abbott has got the green light for its
Eli Lilly is determined not to be left behind when it comes to manufacturing capacity for new diabetes and obesity therapies, raising its spending on a new plant in Indian